EGFR 突变 NSCLC 小细胞转化后的治疗与结局：国际回顾性研究
类型: 国际回顾性研究 发表日期: 2025-06-24 入库日期: 2026-05-21 来源: PubMed / ESMO Open 标签: EGFR L858R, 小细胞转化, 铂依托泊苷, 免疫治疗, 再活检
Citation
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study. ESMO Open. 2025. PMID: 40561657. DOI: 10.1016/j.esmoop.2025.105326
Why it matters for mom
Because mom has baseline RB1/TP53 alterations and had an NSE spike in March 2026, transformed SCLC is a watch item. This study is useful because it focuses on what happens after transformation is confirmed, including chemotherapy, EGFR-TKI continuation questions, and the uncertain role of immune checkpoint inhibitors.
Practical takeaways
- Small-cell transformation is a diagnosis that requires pathology, not just NSE.
- If confirmed, treatment often shifts toward small-cell-style chemotherapy, commonly platinum/etoposide-based.
- Immunotherapy benefit in EGFR-transformed SCLC remains uncertain and should not be assumed from de novo SCLC data.
Questions for doctors
- If transformation is suspected, which lesion is best to biopsy?
- If confirmed, should treatment follow SCLC protocols, and should osimertinib be continued for EGFR-mutant adenocarcinoma components/CNS protection?
- Is there any role for immunotherapy in this exact transformed-EGFR setting?